Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime infusion strategy pharmacokinetic trial in ICU sepsis
ACTRN12609000069257Phase 4Recruiting
- Sponsor
- Alfred Health
- Start
- Feb 2009
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefepime in sepsis (3 arms), sponsored by Alfred Health. Primary endpoints: Percentage of dosing interval above pharmacodynamic breakpoint during first 12 hours, Percentage of dosing interval above pharmacodynamic breakpoint at steady state and 1 more. Started Feb 2009; status: recruiting.
02
Drugs
cefepime
03
Conditions
sepsis
Beyond the preview
Go deeper on ACTRN12609000069257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000069257.